Vermillion & White Wealth Management Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,000	Closed	-$36.8K	–	333
2025 Q4	$36.8K	Sell	32,000 -500	-2%	-$687	0.02%	183
2025 Q3	$43.9K	Buy	32,500 +26,000	+400%	+$29.5K	0.03%	165
2025 Q2	$6.15K	Buy	+6,500	New	+$4.21K	﹤0.01%	347
2025 Q1	–	Sell	-13,415	Closed	-$9.91K	–	544
2024 Q4	$9.91K	Hold	13,415	–	–	0.01%	235
2024 Q3	$21.1K	Buy	13,415 +1,000	+8%	+$1.78K	0.02%	178
2024 Q2	$20.9K	Hold	12,415	–	–	0.02%	181
2024 Q1	$29.8K	Buy	+12,415	New	+$26.7K	0.02%	154

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vermillion & White Wealth Management Group's LXRX Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 32,000 shares — an estimated $36.8K sold.

Vermillion & White Wealth Management Group first reported a position in LXRX in Q1 2024 and held it in 7 quarters. The position peaked at $43.9K in Q3 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Vermillion & White Wealth Management Group reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Vermillion & White Wealth Management Group sold 32,000 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $36.8K.
Vermillion & White Wealth Management Group first reported a position in Lexicon Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Vermillion & White Wealth Management Group's Lexicon Pharmaceuticals position peaked at $43.9K in Q3 2025.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.